- Stockholders approved conversion of Series A preferred stock into common shares, introducing dilution risk.
- Rebranding to Azora Therapeutics with new ticker 'AZR' taking effect October 29.
- Clinical Phase 1 initiation for lead asset AT177 not expected until first half of 2027.
?? Negative AI Sentiment (-1.5 / 10)